keyword
MENU ▼
Read by QxMD icon Read
search

Pemphigoid

keyword
https://www.readbyqxmd.com/read/29136295/genome-wide-association-study-identifies-galc-as-susceptibility-gene-for-mucous-membrane-pemphigoid
#1
C D Sadik, J Bischof, N van Beek, A Dieterich, S Benoit, M Sárdy, M Worm, S Meller, R Gläser, D Zillikens, B Homey, J Setterfield, D Minassian, E Schmidt, J Dart, S M Ibrahim
BACKGROUND: Mucous membrane pemphigoid (MMP) is a rare, chronic, and often aggressive subepidermal autoimmune blistering disease potentially affecting several mucous membranes with blisters and secondary erosions and scars. The pathogenesis of MMP is poorly understood, and the contribution of genetic predispositions, other than HLA class II allele variants to MMP, is unknown. OBJECTIVES: The objective of this study is to identify susceptibility genes for MMP in a British cohort of MMP patients...
November 14, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/29136264/biological-and-clinical-response-to-omalizumab-in-a-patient-with-bullous-pemphigoid
#2
Sébastien Menzinger, Gürkan Kaya, Enno Schmidt, Lionel Fontao, Emmanuel Laffitte
No abstract text is available yet for this article.
November 14, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29135016/light-chain-deposition-disease-with-bullous-skin-lesions-mimicking-atypical-bullous-pemphigoid
#3
Marion Malphettes, Pauline Bonnet, Pierre Schneider, Marguerite Vignon, Marine Baron, Jean-David Bouaziz, Maxime Battistella
No abstract text is available yet for this article.
August 23, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29131038/bullous-diseases
#4
Caroline Corbaux, Pascal Joly
Autoimmune bullous diseases are a heterogeneous group of blistering diseases affecting the skin and/or mucous membrane. Systemic corticosteroids, which are often associated with immunosuppressants, are the main treatment option for these diseases. The 2 main biologics used in the treatment of autoimmune bullous diseases are rituximab, especially in pemphigus and mucous membrane pemphigoid, and omalizumab in bullous pemphigoid. Rituximab is a promising therapeutic option in pemphigus and mucous membrane pemphigoid...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29130487/a-case-of-mucous-membrane-pemphigoid-with-igg-antibodies-against-the-%C3%AE-3-and-%C3%AE-2-subunits-of-laminin-332-and-the-c-terminal-domain-of-bp180
#5
Makiko Yasumizu, Hisayoshi Imanishi, Shosuke Morita, Aoi Fukuda, Chiharu Tateishi, Hiroshi Koga, Takashi Hashimoto, Daisuke Tsuruta
No abstract text is available yet for this article.
November 11, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/29124728/generating-new-evidence-improving-clinical-practice-and-developing-research-capacity-the-benefits-of-recruiting-to-the-u-k-dermatology-clinical-trials-network-s-stop-gap-and-blister-trials
#6
J M Batchelor, A Chapman, F E Craig, K E Harman, G Kirtschig, A Martin-Clavijo, A D Ormerod, S Walton, H C Williams
Clinical trials may benefit clinical practice in three ways: firstly, clinicians may change their practice according to the new trial evidence; secondly, clinical processes can improve when working on a trial; and thirdly, research capacity is increased. We held a meeting to present and discuss the results of two large multicentre randomized controlled trials delivered through the U.K. Dermatology Clinical Trials Network. Investigators gave reflections on how the trials had changed their clinical practice. The STOP GAP trial showed that prednisolone and ciclosporin are equally effective as first-line systemic treatment for pyoderma gangrenosum...
November 10, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29111983/acute-flare-of-bullous-pemphigus-with-pembrolizumab-used-for-treatment-of-metastatic-urothelial-cancer
#7
Rohan Garje, Justin J Chau, Jina Chung, Karolyn Wanat, Yousef Zakharia
In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities...
November 3, 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29105148/biomarkers-related-to-bullous-pemphigoid-activity-and-outcome
#8
REVIEW
Delphine Giusti, Sébastien Le Jan, Gregory Gatouillat, Philippe Bernard, Bach Nga Pham, Frank Antonicelli
Bullous pemphigoid (BP) is the most common autoimmune sub-epidermal blistering disease of the skin. Investigation of the BP-associated pathophysiological processes during the last decades showed that the generation of auto-antibodies directed against the hemidesmosome proteins BP180 and BP230, a hallmark of the BP-associated autoimmune response, leads to the recruitment of inflammatory immune cells at the dermal-epidermal junction, and subsequently to the release of a large amount of inflammatory molecules involved in blister formation...
November 3, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/29102490/nonbullous-cutaneous-pemphigoid-a-systematic-review
#9
REVIEW
Aniek Lamberts, Joost M Meijer, Marcel F Jonkman
BACKGROUND: Cutaneous pemphigoid (bullous pemphigoid) is an autoimmune bullous disease that typically presents with tense bullae and severe pruritus. However, bullae may be lacking, a subtype termed nonbullous cutaneous pemphigoid. OBJECTIVE: To summarize the reported characteristics of nonbullous cutaneous pemphigoid. METHODS: The EMBASE and MEDLINE databases were searched using 'nonbullous cutaneous pemphigoid' and various synonyms. Case reports and series describing nonbullous cutaneous pemphigoid were included...
November 1, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29090462/ethnic-variations-in-the-epidemiology-of-bullous-pemphigoid-in-israel
#10
Khalaf Kridin, Reuven Bergman
BACKGROUND: No ethnic or geographic predisposition to bullous pemphigoid (BP) was reported so far. OBJECTIVE: To evaluate trends in the incidence of BP in northern Israel, shedding light on differences between two distinct ethnic populations who inhabit the same region, namely Jews and Arabs. METHODS: Bullous pemphigoid incidence was retrospectively estimated from January 2000-December 2015 in two Israeli regions with a total population of 1...
October 31, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/29079272/modulation-of-fibroblasts-in-conjunctival-wound-healing
#11
REVIEW
Mark Zada, Ushasree Pattamatta, Andrew White
Modulating conjunctival wound healing has the potential to improve outcomes after glaucoma filtration surgery and for several ocular disorders, including ocular cicatrial pemphigoid, vernal keratoconjunctivitis, and pterygium. Although anti-inflammatories and antimetabolites have been used with success, these nonspecific agents are not without their complications. The search for novel and more targeted means to control conjunctival fibrosis without such limitations has brought much attention to the regulation of fibroblast proliferation, differentiation, extracellular matrix production, and apoptosis...
October 24, 2017: Ophthalmology
https://www.readbyqxmd.com/read/29077176/long-term-remission-of-ocular-cicatricial-pemphigoid-off-immunomodulatory-therapy
#12
Caiyun You, Lina Ma, Stephen D Anesi, C Stephen Foster
PURPOSE: To evaluate whether long-term remission of ocular cicatricial pemphigoid (OCP) after withdrawal of immunomodulatory therapy (IMT) is possible. METHODS: A total of 34 of 464 presenting patients (66 eyes) with biopsy-proven OCP in long-term remission off IMT were identified after finishing a 2-year IMT regimen without active disease (2005-2015). Long-term remission off IMT for OCP was defined as patients withdrawn from IMT ≥1 year lacking clinically detectable progressive scarring according to Foster staging and subjective assessment...
October 14, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29071428/ige-autoantibodies-and-their-association-with-the-disease-activity-and-phenotype-in-bullous-pemphigoid-a-systematic-review
#13
REVIEW
Ariadne Hadjikyriacou Saniklidou, Patrick J Tighe, Lucy C Fairclough, Ian Todd
Bullous pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII collagen (COL17) protein acting as the adhesion molecule between the epidermis and the basement membrane of the dermis. About 40 years ago, following consistent findings of elevated total serum IgE levels in BP patients, it was hypothesized that IgE may be involved in the pathophysiology of BP...
October 25, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/29066238/ocular-features-of-multiple-system-atrophy
#14
Maria D Garcia, Jose S Pulido, Elizabeth A Coon, John J Chen
The aim of this paper is to gain better understanding of the ocular manifestations of multiple system atrophy (MSA), a neurodegenerative disorder rarely studied in terms of its ophthalmologic features. We performed a retrospective case series (1/1/05-12/31/14) to search for patients seen at Mayo Clinic, Rochester, MN, who had mention of MSA in the medical record and an eye examination, which yielded 285 cases. Of the 285, we identified 39 cases of true MSA. Each of these 39 patients was further reviewed for ocular abnormalities potentially related to MSA...
October 21, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29055144/increased-prevalence-of-diabetes-mellitus-in-bullous-pemphigoid-patients-during-the-last-decade
#15
Luca Fania, Giovanni Di Zenzo, Biagio Didona, Maria Antonietta Pilla, Luciano Sobrino, Annarita Panebianco, Cinzia Mazzanti, Damiano Abeni
Bullous pemphigoid (BP) is a rare autoimmune blistering disease. The association between BP and diabetes mellitus (DM) has been previously reported with inconsistent results(1-4) . Dipeptidyl peptidase (DPP)-IV inhibitors, approved in Europe by EMA in 2007 to treat type-2 DM, are antihyperglycemic drugs that could induce BP disease(5-9) . This article is protected by copyright. All rights reserved.
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29054606/semaphorin-4d-from-cd15-granulocytes-via-adam10-induced-cleavage-contributes-to-antibody-production-in-bullous-pemphigoid
#16
Shengxian Shen, Yao Ke, Erle Dang, Hui Fang, Yuqian Chang, Jieyu Zhang, Zhenlai Zhu, Shuai Shao, Pei Qiao, Tongmei Zhang, Hongjiang Qiao, Gang Wang
Autoreactive B cells activation and antibody production are critical events for the development of bullous pemphigoid (BP). However, the mechanism that is involved in the modulation of B cell activation and autoantibody generation has not been fully understood. Semaphorin 4D (Sema4D/CD100) plays important roles in immune regulation related to B cell, but its implication in BP remains obscure. The aim of our study was to characterize Sema4D and the underlying mechanism contributing to the autoimmune features of BP...
October 17, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29052880/endoscopic-characteristics-of-oesophagus-involvement-in-mucous-membrane-pemphigoid
#17
COMMENT
H Yuan, M Pan
No abstract text is available yet for this article.
October 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29040970/use-of-dipeptidyl-peptidase-iv-inhibitors-and-bullous-pemphigoid
#18
Clara Schaffer, Thierry Buclin, Francois R Jornayvaz, Simone Cazzaniga, Luca Borradori, Michel Gilliet, Laurence Feldmeyer
No abstract text is available yet for this article.
October 18, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/29033436/bullous-pemphigoid-presenting-with-esophagitis-dissecans-superficialis
#19
Kunimitsu Inoue, Tomoya Okajima, Osamu Okamoto, Kazunari Murakami
No abstract text is available yet for this article.
October 16, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29028121/lupus-like-cutaneous-reaction-following-pembrolizumab-an-immune-related-adverse-event-associated-with-anti-pd-1-therapy
#20
Kimberly Shao, Suzanne McGettigan, Rosalie Elenitsas, Emily Y Chu
PD-1 (programmed cell death-1) inhibitors, used to treat metastatic melanoma and other malignancies, are associated with development of immune-related adverse events in the skin. Such reactions include morbilliform eruptions, vitiligo, alopecia areata, and bullous pemphigoid. In this report, we describe a patient who developed a lupus-like cutaneous reaction in the setting of pembrolizumab therapy for metastatic melanoma, adding to the spectrum of reactions which may be observed in association with PD-1 inhibitor therapy...
October 13, 2017: Journal of Cutaneous Pathology
keyword
keyword
625
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"